Icahn School of Medicine at Mount Sinai-ko ikertzaileekin lankidetzan egindako argitalpenak (9)

2024

  1. Correction to: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review (Blood Cancer Journal, (2024), 14, 1, (24), 10.1038/s41408-023-00966-9)

    Blood Cancer Journal

  2. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review

    Blood Cancer Journal, Vol. 14, Núm. 1

2023

  1. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

    Blood cancer journal

  2. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma

    Future Oncology, Vol. 19, Núm. 27, pp. 1823-1840

2022

  1. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

    The New England journal of medicine, Vol. 387, Núm. 24, pp. 2232-2244

2021

  1. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study

    British Journal of Haematology, Vol. 192, Núm. 5, pp. 869-878

2020

  1. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

    The Lancet Oncology, Vol. 21, Núm. 2, pp. 207-221

2019

  1. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Blood, Vol. 134, Núm. 5, pp. 421-431

2017

  1. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

    Leukemia, Vol. 31, Núm. 11, pp. 2443-2448